Abstract
Quinazoline scaffold has been successfully utilized for development of various inhibitors of tubulin, epidermal growth factor receptor (EGFR), polo like kinases (PLKs), Hedgehog-Gli signaling pathway and protein kinase B (PKB) /Akt pathway. Compounds based on quinazolines have shown efficacies in µM to nM range in various cancer cell lines and thus could be useful scaffolds for development of both apoptosis inducers as well as inhibitors. This compilation is based on various patents published till 2015 and divides the quinazolines in two main categories: Quinazolines as apoptosis inducers and as apoptosis inhibitors. These two main categories are further sub-categorized based on the use/pharmacological indications for these classes of patented compounds. This review will act as a tool for the researchers working on exploring the anticancer potential of quinazoline as a privileged heterocyclic. The promising anticancer profile of some of the quinazoline based compounds clearly highlights the clinical potential of this heterocycle.
Keywords: Apoptosis inducers, apoptosis inhibitors, cancer, caspases, p53, tubulin, quinazolines.
Recent Patents on Anti-Cancer Drug Discovery
Title:Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Volume: 11 Issue: 1
Author(s): Samir Mehndiratta, Sameer Sapra, Gurpreet singh, Manwinder Singh and Kunal Nepali
Affiliation:
Keywords: Apoptosis inducers, apoptosis inhibitors, cancer, caspases, p53, tubulin, quinazolines.
Abstract: Quinazoline scaffold has been successfully utilized for development of various inhibitors of tubulin, epidermal growth factor receptor (EGFR), polo like kinases (PLKs), Hedgehog-Gli signaling pathway and protein kinase B (PKB) /Akt pathway. Compounds based on quinazolines have shown efficacies in µM to nM range in various cancer cell lines and thus could be useful scaffolds for development of both apoptosis inducers as well as inhibitors. This compilation is based on various patents published till 2015 and divides the quinazolines in two main categories: Quinazolines as apoptosis inducers and as apoptosis inhibitors. These two main categories are further sub-categorized based on the use/pharmacological indications for these classes of patented compounds. This review will act as a tool for the researchers working on exploring the anticancer potential of quinazoline as a privileged heterocyclic. The promising anticancer profile of some of the quinazoline based compounds clearly highlights the clinical potential of this heterocycle.
Export Options
About this article
Cite this article as:
Mehndiratta Samir, Sapra Sameer, singh Gurpreet, Singh Manwinder and Nepali Kunal, Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (1) . https://dx.doi.org/10.2174/1574892811666151218151506
DOI https://dx.doi.org/10.2174/1574892811666151218151506 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery A Walk in Nature: Sesquiterpene Lactones as Multi-Target Agents Involved in Inflammatory Pathways
Current Medicinal Chemistry Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Determination of Dysregulated miRNA Expression Levels by qRT-PCR after the Application of Usnic Acid to Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Integrative Neurochemistry and Neurobiology of Social Recognition and Behavior Analyzed with Respect to CD38-Dependent Brain Oxytocin Secretion
Current Topics in Medicinal Chemistry Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds Role of Progesterone in Human Astrocytomas Growth
Current Topics in Medicinal Chemistry Integrin-Mediated Drug Resistance
Current Signal Transduction Therapy The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Resveratrol and Ischemic Preconditioning in the Brain
Current Medicinal Chemistry Magnetic Hyperthermia with Magnetic Nanoparticles: A Status Review
Current Topics in Medicinal Chemistry CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Molecular Imaging of Brain Tumors Personal Experience and Review of the Literature
Current Molecular Medicine